Skip to main content
Scientific publications

At Day One, we use the power of leading-edge science to improve patient outcomes.

We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
Nov 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Kilburn LB, Khuong-Quang D-A, Hansford JR, Landi D, van der Lugt J, Leary SES, Hernáiz Driever P, Bailey S, Perreault S, McCowage G, Waanders AJ, Ziegler DS, Witt O, Baxter PA, Kang HJ, Hassall TE, Han JW, Hargrave D, Franson AT, Oren MY, Toledano H, Larouche V, Kline C, Abdelbaki MS, Jabado N, Gottardo NG, Gerber NU, Whipple NS, Segal D, Chi SN, Oren L, Tan EEK, Mueller S, Cornelio I, McLeod L, Zhao X, Walter A, Da Costa D, Manley P, Blackman SC, Packer RJ, Nysom K.
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial [published online ahead of print November 17, 2023]. Nat Med. 2023.
Nov 2023
Preliminary clinical activity of the type II RAF inhibitor tovorafenib in RAF-fusion-driven recurrent/progressive sarcomas.
van Eijkelenburg Natasha KA, van der Lugt J, Da Costa D, Manley P, Hume S, Kopp LM, Lee J.
Abstract 1552798. Preliminary clinical activity of the type II RAF inhibitor tovorafenib in RAF-fusion-driven recurrent/progressive sarcomas. Poster presentation at: The CTOS (Connective Tissue Oncology Society) 2023 Annual Meeting; November 1-4, 2023; Dublin, Ireland
July 2023
Activity of RAF Inhibitor Tovorafenib in a Pediatric Patient with a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion
Offer K, McGuire MT, Song K, Goldfischer MJ, Davare MA, Corless CL, Beadling C, Neff T, Cox MC, Raju SG, Blackman SC. Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient with a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion [published online ahead of print July 6, 2023]. JCO Precis Oncol. 2023;7.
June 2023
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.
Kilburn L, Khuong-Quang D-A, Nysom K, Landi D, Ziegler DS, Hernáiz Driever P, Leary S, Bailey S, Van der Lugt J, Perreault S, Waanders AJ, Baxter P, Witt O, Hargrave D, McCowage G, Zhao X, Da Costa D, Cox MC, Manley P, Hansford JR. LGG-09. Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. Neuro-Oncol. 2023(suppl 1);i57. (ABSTRACT CITATION ID: NOAD073.218)
June 2023
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFL Y-1 (PNOC026) study
Lindsay Kilburn, Dong-Anh Khuong-Quang, Karsten Nysom, Daniel Landi, David S. Ziegler, Pablo Hernaiz Driever, Sarah Leary, Simon Bailey, Jasper Van der Lugt, Sebastien Perreault, Angela J. Waanders, Patricia Baxter, Olaf Witt, Darren Hargrave, Geoffrey McCowage, Xin Zhao, Daniel Da Costa, Michael C. Cox, Peter Manley, Jordan R. Hansford
2023 ASCO Annual Meeting, June 2-6, 2023, Chicago, IL & Online. Abstract number 10004
June 2023
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
Cornelis M. van Tilburg, Lindsay Kilburn, Erin Crotty, Amy A. Smith, Sebastien Perreault, Andrea T. Franson, Nada Jabado, Lindsey M. Hoffman, Rene Schmidt, Antoinette Y.N. Schoutenvan Meeteren, Astrid Sehested, Enrico Opocher, Pablo Hernáiz Driever, Shivaram Avula, David S. Ziegler, Jiaheng Qiu, Li-Pen Tsao, Peter Manley, Darren Hargrave, Olaf Witt
ASCO Annual Meeting 2023: Abstract TPS10067